Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 52 min ago
Peer-reviewedCC BY 4.0Genetics Research

A Single‐Cell‐Derived Proliferative Signature Is Associated With Progression‐Free Survival During Immunotherapy and Sunitinib Treatment in Clear Cell Renal Cell Carcinoma

4 affiliations
  1. 1Department of Urology Tianjin First Central Hospital Tianjin 300071 China tj-fch.com
  2. 2The First Central Clinical School Tianjin Medical University Tianjin 300071 China tijmu.edu.cn
  3. 3Department of Urology The First Affiliated Hospital of Xinxiang Medical University Weihui Henan 453100 China xxmu.edu.cn
  4. 4Tianjin First Central Hospital Nankai University Tianjin 300071 China nankai.edu.cn

Abstract

Background: Resistance to immune checkpoint inhibitors and VEGFR‐targeted agents limits durable disease control in clear cell renal cell carcinoma (ccRCC). We examined a tumour cell proliferative transcriptional programme in relation to treatment response and progression‐free survival (PFS).

Methods: We analysed predominantly unpaired baseline and progression single‐cell transcriptomes from anti‐PD‐1‐treated ccRCC. A fixed 20‐gene signature underwent patient‐adjusted pseudobulk and RNA‐inferred copy‐number analyses. Pretreatment scores were evaluated in 332 patients across four immunotherapy or sunitinib groups from three studies, with established proliferation benchmarks and time‐varying survival analyses.

Results: The discovery comparison included five baseline and six progression patients. All 20 genes, including PLK1, UBE2C and CDC20, retained higher expression in the proliferative cluster after patient adjustment, although its abundance difference did not survive multiple‐testing correction (BH‐adjusted q = 0.164). The score closely tracked G2M (r = 0.915–0.980), without superior PFS discrimination in the primary benchmark. Inclusive response AUCs were 0.519 for IMmotion150 immunotherapy, 0.569 for IMmotion150 sunitinib and 0.693 for E‐MTAB‐3267. In E‐MTAB‐3267, the age‐ and sex‐adjusted HR was 1.54 per score standard deviation (95% CI 1.13–2.11). The IMmotion150 immunotherapy association weakened over follow‐up; excluding this nonproportional estimate yielded a pooled HR of 1.51 (95% CI 1.24–1.83) in 158 patients.

Conclusion: Single‐cell and bulk transcriptomic analyses connect a proliferative gene‐expression programme with adverse PFS during immunotherapy and sunitinib treatment in ccRCC. The signature provides a compact transcriptional readout of proliferation associated with treatment outcomes, with a stronger relationship to PFS than to objective response.

Related

  1. Multi-omics profiling uncovers diagnostic biomarker panel, progression-associated subtypes, and prognostic signature in pediatric mitochondrial disease
    Xiaoting Lou, Zhehui Chen, Yuwei Zhou +11
    Nature CommunicationsPeer-reviewedCC BY-NC-ND 4.0Full textGeneral medicineCrossrefPMC
  2. A CAVIN1/SULF1-associated myCAF signature predicts metastatic progression in colorectal cancer
    Bahareh Maleki, Laleh Shariati, Zohreh Hojati
    Scientific ReportsPeer-reviewedCC BY 4.0Full textOncologyCrossref
  3. A kbhb-associated prognostic signature identifies TTLL12 as a promoter of lung adenocarcinoma progression associated with M2 macrophage infiltration.
    Sixuan Wu, Yi Xun, Yiling Jiang +1
    Biology directPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMCPMC
  4. Metabolic signature of phosphoethanolamine and arginine pathways predicts prognosis and immunotherapy resistance in lung adenocarcinoma
    Tao Wang, Hongwei Li, Fei Ding
    Translational cancer researchPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  5. Machine learning based regulatory T cells related gene signature for predicting the clinical outcome and immunotherapy benefits in skin cutaneous melanoma
    Yuzhi Zheng, Xinnuo Chen, Zijian Wu +2
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textOncologyCrossref
BibTeX
@article{li2026singlecellderived,
  title = {{A Single‐Cell‐Derived Proliferative Signature Is Associated With Progression‐Free Survival During Immunotherapy and Sunitinib Treatment in Clear Cell Renal Cell Carcinoma}},
  author = {Zeyu Li and Shaoqiang Xing and Sheng Zeng and Yifei Zhang and Yaowen Li and Qian Liu},
  journal = {Genetics Research},
  year = {2026},
  month = nov,
  doi = {10.1155/genr/4050985},
  url = {https://doi.org/10.1155/genr/4050985},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - A Single‐Cell‐Derived Proliferative Signature Is Associated With Progression‐Free Survival During Immunotherapy and Sunitinib Treatment in Clear Cell Renal Cell Carcinoma
AU  - Zeyu Li
AU  - Shaoqiang Xing
AU  - Sheng Zeng
AU  - Yifei Zhang
AU  - Yaowen Li
AU  - Qian Liu
PY  - 2026
DA  - 2026/11/09
JO  - Genetics Research
DO  - 10.1155/genr/4050985
UR  - https://doi.org/10.1155/genr/4050985
AB  - Background: Resistance to immune checkpoint inhibitors and VEGFR‐targeted agents limits durable disease control in clear cell renal cell carcinoma (ccRCC). We examined a tumour cell proliferative transcriptional programme in relation to treatment response and progression‐free survival (PFS).  Methods: We analysed predominantly unpaired baseline and progression single‐cell transcriptomes from anti‐PD‐1‐treated ccRCC. A fixed 20‐gene signature underwent patient‐adjusted pseudobulk and RNA‐inferred copy‐number analyses. Pretreatment scores were evaluated in 332 patients across four immunotherapy or sunitinib groups from three studies, with established proliferation benchmarks and time‐varying survival analyses.  Results: The discovery comparison included five baseline and six progression patients. All 20 genes, including PLK1, UBE2C and CDC20, retained higher expression in the proliferative cluster after patient adjustment, although its abundance difference did not survive multiple‐testing correction (BH‐adjusted q = 0.164). The score closely tracked G2M (r = 0.915–0.980), without superior PFS discrimination in the primary benchmark. Inclusive response AUCs were 0.519 for IMmotion150 immunotherapy, 0.569 for IMmotion150 sunitinib and 0.693 for E‐MTAB‐3267. In E‐MTAB‐3267, the age‐ and sex‐adjusted HR was 1.54 per score standard deviation (95% CI 1.13–2.11). The IMmotion150 immunotherapy association weakened over follow‐up; excluding this nonproportional estimate yielded a pooled HR of 1.51 (95% CI 1.24–1.83) in 158 patients.  Conclusion: Single‐cell and bulk transcriptomic analyses connect a proliferative gene‐expression programme with adverse PFS during immunotherapy and sunitinib treatment in ccRCC. The signature provides a compact transcriptional readout of proliferation associated with treatment outcomes, with a stronger relationship to PFS than to objective response.
SN  - 0016-6723
SN  - 1469-5073
ER  -